EDINBURGH, Scotland, Aug. 28,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that it has received a patent grant from European Patent Office
(EPO) covering the use of modified gamma delta cells for the
treatment of cancer and viral indications.
The Company intends to proceed with the patent process
in specific European countries in line with the commercial strategy
of TCBP.
"We are pleased to further expand our patent portfolio
at TCBP with this European patent for Modified Gamma Delta t-cells"
said Bryan Kobel, CEO of TC BioPharm. "TCBP
continues to focus on our immediate applications for TCB008 while
developing future high value gamma delta assets for other
indications such as solid tumors. We believe gamma deltas can be a
high impact therapeutic when modified with the potential to outpace
current CAR and modified t-cells in safety and
efficacy, patent protecting these approaches gives us a
competitive moat and further value in a potential acquisition
scenario."
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this Current Report on Form 8-K that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the Company's
intent or ability to affect any budget savings or execute on any
M&A or capital raising strategy. These statements are based on
management's current assumptions and are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause the Company's actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. For other important
factors that could cause actual results to differ materially from
the forward-looking statements in this Current Report on Form 8-K,
please see the risks and uncertainties identified under the heading
"Risk Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2023, and our other
reports filed with the SEC, all of which is available on the
Company's Investor Relations website
at www.tcbiopharm.com and on the SEC website
at www.sec.gov. All forward-looking statements reflect the
Company's beliefs and assumptions only as of the date of this press
release. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC
BioPharm is the leader in developing gamma-delta T cell therapies,
and the first company to conduct phase II/pivotal clinical studies
in oncology. The Company is conducting two investigator-initiated
clinical trials for its unmodified gamma-delta T cell product line
- Phase 2b/3 pivotal trial in
treatment of acute myeloid leukemia using the Company's proprietary
allogeneic CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-grant-of-european-patent-covering-use-of-modified-gamma-delta-cells-for-the-treatment-of-cancer-and-viral-indications-302233266.html
SOURCE TC BioPharm
